

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | Complete if Known | |
|-------|---|----|----|------------------------|------------------------------|
| | | | | Application Number | 10/737,262 |
| | | | | Filing Date | 12/15/03 |
| | | | | First Named Inventor | Leonidas Stefanis |
| | | | | Art Unit | 1632 1649 |
| | | | | Examiner Name | to be assigned Daniel Kolker |
| Sheet | 1 | of | 17 | Attorney Docket Number | 5199-26 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| JK | | Ancolio et al., alpha-Synuclein and the Parkinson's disease-related mutant Ala53Thr-alpha-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells. | |
| | | Neurosci. Lett., 285: 79-82, 2000 | |
| | | Anglade et al., Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. | |
| | | Histol. Histopathol., 12: 25-31, 1997 | |
| | | Baba et al., Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. | |
| | | Am. J. Pathol., 152: 879-884, 1998 | |
| | | Brunk et al., Exposure of cells to nonlethal concentrations of hydrogen peroxide induces degeneration-repair mechanisms involving lysosomal destabilization. | |
| ✓ | | Free Radic. Biol. Med., 19: 813-822, 1995 | |

| | | | |
|--------------------|----------------------|-----------------|--------|
| Examiner Signature | <i>Daniel Kolker</i> | Date Considered | 2/2/06 |
|--------------------|----------------------|-----------------|--------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|--|-------|--------------------------------|-----------------------------------|--|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | (Use as many sheets as necessary) | |
| Sheet 2 | | of 17 | Attorney Docket Number 5199-26 | | |
| | | | | | |

| NON PATENT LITERATURE DOCUMENTS | | | | | |
|---------------------------------|-----------------------|---|--|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | T ² |
| DK | | Burke, Apoptosis in degenerative diseases of the basal ganglia. | | | |
| | | The Neuroscientist, 4: 301-311, 1998 | | | |
| | | Bursch et al., programmed cell death (PCD). Apoptosis, autophagic PCD, or others? | | | |
| | | Ann. NY Acad. Sci., 926: 1-12, 2000 | | | |
| | | Cavanagh et al., Routes of excretion of neuronal lysosomal dense bodies after ventricular infusion of leupeptin in the rat: a study using ubiquitin and | | | |
| | | PGP 9.5 immunocytochemistry. | | | |
| | | J. Neurocytol., 22: 779-791, 1993 | | | |
| | | Ciechanover, The ubiquitin-proteasome pathway: on protein death and cell life. | | | |
| ✓ | | EMBO J., 17: 7151-7160, 1998 | | | |
| | | | | | |
| | | | | | |

| | | | |
|--------------------|---|-----------------|--------|
| Examiner Signature |  | Date Considered | 2/2/06 |
|--------------------|---|-----------------|--------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

3

of

17

Application Number

10/737,262

Filing Date

12/15/03

First Named Inventor

Leonidas Stefanis

Art Unit

1632-1649


Examiner Name

to be assigned

Attorney Docket Number

5199-26

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| DK | | Clayton and George, The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration, and disease. | |
| | | Trends Neurosci., 21: 249-254, 1998 | |
| | | Clayton and George, Synucleins in synaptic plasticity and neurodegenerative disorders. | |
| | | J. Neurosci. Res., 58: 120-129, 1999 | |
| | | Clarke, Developmental cell death: morphological diversity and multiple mechanisms. | |
| | | Anat. Embryol. (Berl), 181: 195-213, 1990 | |
| | | Conway et al., Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. | |
| | | Nat. Med., 11: 1318-1320, 1998 | |
| ✓ | | Fahn and Przedborski, Parkinsonism. In: Merritt's textbook of neurology, Ed 10 (Rowland LP, ed), pp 679-693. Philadelphia: Williams & Wilkins 2000 | |
| | | | |
| | | | |

| | | | |
|--------------------|---|-----------------|--------|
| Examiner Signature |  | Date Considered | 2/2/06 |
|--------------------|---|-----------------|--------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|---|--------------------------|-------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | Complete if Known | |
| | | Application Number | 10/737,262 |
| | | Filing Date | 12/15/03 |
| | | First Named Inventor | Leonidas Stefanis |
| | | Art Unit | 1632-1649 |
| | | Examiner Name | to be assigned |
| Sheet | 4 | of | 17 |
| | | Attorney Docket Number | 5199-26 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| PK | | Figueiredo-Pereira et al., A new inhibitor of the chymotrypsin-like activity of the multicatalytic proteinase complex (20S proteasome) induces | |
| | | accumulation of ubiquitin-protein conjugates in a neuronal cell. | |
| | | J. Neurochem., 63: 1578-1581, 1994 | |
| | | Fon et al., Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. | |
| | | Neuron, 19: 1271-1283, 1997 | |
| | | Forno and Norville, Ultrastructure of Lewy bodies in the stellate ganglion. | |
| | | Acta. Neuropathol. (Berl), 34: 183-197, 1976 | |
| | | Furlong et al., Alpha-synuclein over expression promotes aggregation of mutant huntingtin. | |
| ↓ | | Biochem. J., 15: 577-581, 2000 | |
| | | | |
| | | | |

| | | | |
|--------------------|---|-----------------|--------|
| Examiner Signature |  | Date Considered | 2/2/06 |
|--------------------|---|-----------------|--------|


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|----|------------------------|-------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/737,262 |
| | | | | Filing Date | 12/15/03 |
| | | | | First Named Inventor | Leonidas Stefanis |
| | | | | Art Unit | 1649 |
| | | | | Examiner Name | to be assigned |
| Sheet | 5 | of | 17 | Attorney Docket Number | 5199-26 |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-----------------------|---|--|--|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | |
| DK | | Ghee et al., Rat alpha-synuclein interacts with tat binding protein 1, a component of the 26S proteasomal complex. | | |
| | | J. Neurochem., 75: 2221-2224, 2000 | | |
| | | Goldstein and Greene, Activation of tyrosine hydroxylase by phosphorylation. In: Psychopharmacology: a third generation of progress | | |
| | | (Meltzer H, ed), pp 75-80. New York: Raven, 1987 | | |
| | | Greene and Tischler, Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. | | |
| | | Proc. Natl. Acad. Sci. USA 73: 2424-2428, 1976 | | |
| | | Greene, et al., Culture and experimental use of the PC12 rat pheochromocytoma cell line. In: Culturing nerve cells (Banker G, Goslin K, eds), pp 161-189. | | |
| | | Cambridge, MA: MIT Press, 1998; Stefanis et al., 2001, supra). | | |
| | | Hornykiewicz, Dopamine (3-hydroxytyramine) and brain function. | | |
| ✓ | | Pharmacol. Rev., 18: 925-965, 1996 | | |

| | | | |
|--------------------|---|-----------------|--------|
| Examiner Signature |  | Date Considered | 2/2/08 |
|--------------------|---|-----------------|--------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | |
|--|--------------|--------------------------|-------------------|--|
| Substitute for form 1449/PTO | | Complete if Known | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | Application Number | 10/737,262 | |
| | | Filing Date | 12/15/03 | |
| | | First Named Inventor | Leonidas Stefanis | |
| | | Art Unit | 1632 → 1649 | |
| | | Examiner Name | to be assigned | |
| Sheet 6 | of 17 | Attorney Docket Number | 5199-26 | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| JK | | Hsu et al., Alpha-Synuclein promotes mitochondrial deficit and oxidative stress. | |
| | | Am. J. Pathol., 157: 401-410, 2000 | |
| | | Imai et al., An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. | |
| | | Cell, 105: 891-902, 2001 | |
| | | Kanda et al., Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. | |
| | | Neuroscience, 97: 279-284, 2000 | |
| | | Kegel et al., Huntington expression stimulates endosomal-lysosomal activity, endosome tabulation, and autophagy. | |
| | | J. Neurosci., 20: 7268-7278, 2000 | |
| | | Kitada et al., Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. | |
| ↓ | | Nature, 392: 605-608, 1998 | |

| | | | |
|--------------------|-----------------------|-----------------|--------|
| Examiner Signature | <i>Janine E. Kelt</i> | Date Considered | 2/2/06 |
|--------------------|-----------------------|-----------------|--------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|----|--------------------------|-------------------|
| Substitute for form 1449/PTO | | | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/737,262 |
| | | | | Filing Date | 12/15/03 |
| | | | | First Named Inventor | Leonidas Stefanis |
| | | | | Art Unit | 1632-1649 |
| | | | | Examiner Name | to be assigned |
| Sheet | 7 | of | 17 | Attorney Docket Number | 5199-26 |

| NON PATENT LITERATURE DOCUMENTS | | | | | | |
|--|-----------------------|---|--|--|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | | T ² |
| DK | | Leroy et al., The ubiquitin pathway in Parkinson's disease. | | | | |
| | | Nature, 395: 451-452, 1998 | | | | |
| | | Masliah et al., Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. | | | | |
| | | Science, 287: 1265-1269, 2000 | | | | |
| | | Matsuoka et al., Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. | | | | |
| | | Neurobiol. Dis., 8: 535-539, 2001 | | | | |
| | | Mayer et al., Ubiquitin, lysosomes, and neurodegenerative diseases. | | | | |
| | | Ann. NY Acad. Sci., 674: 149-160, 1992 | | | | |
| | | McNaught and Jenner, Proteasomal function is impaired in substantia nigra in Parkinson's disease. | | | | |
| ↓ | | Neurosci. Lett., 297: 191-194, 2001 | | | | |

| | | | |
|--------------------|---|-----------------|--------|
| Examiner Signature |  | Date Considered | 2/2/06 |
|--------------------|---|-----------------|--------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

| | | | |
|--|--------------|--------------------------|-------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | Complete if Known | |
| | | Application Number | 10/737,262 |
| | | Filing Date | 12/15/03 |
| | | First Named Inventor | Leonidas Stefanis |
| | | Art Unit | 1692- 1649 |
| | | Examiner Name | to be assigned |
| Sheet 8 | of 17 | Attorney Docket Number | 5199-26 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| JK | | McNaught et al., Failure of the ubiquitin-proteasome system in Parkinson's disease. | |
| | | Nat. Rev. Neurosci., 2: 589-594, 2001 | |
| | | Neystat, et al., Alpha-synuclein expression in substantia nigra and cortex in Parkinson's disease. | |
| | | Mov. Disord., 14: 417-422, 1999 | |
| | | Ohsawa et al., An ultrastructural and immunohistochemical study of PC12 cells during apoptosis induced by serum deprivation with special reference to autophagy and lysosomal cathepsins. | |
| | | Arch. Histol. Cytol., 61: 395-403, 1998 | |
| | | Ohtani-Kaneko et al., Proteasome inhibitors which induce neurite outgrowth from PC12h cells cause different subcellular accumulations of multi-ubiquitin chains. | |
| | | Neurochem. Res., 23: 1435-1443, 1998 | |

| | | | |
|--------------------|---|-----------------|--------|
| Examiner Signature |  | Date Considered | 2/2/06 |
|--------------------|---|-----------------|--------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete If Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

9

of

17

Application Number

10/737,262

Filing Date

12/15/03

First Named Inventor

Leonidas Stefanis

Art Unit

1649


Examiner Name

to be assigned

Attorney Docket Number

5199-26

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| PK | | Ostrerova et al., Alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. | |
| | | J. Neurosci., 19: 5782-5791, 1999 | |
| | | Ostrerova-Golts et al., The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. | |
| | | J. Neurosci., 20: 6048-6054, 2000 | |
| | | Papadimitriou et al., Mutated alpha-synuclein gene in two Greek kindreds with familial PD: incomplete penetrance? Neurology, 52: 651-654, 1999 | |
| | | Neurology, 52: 651-654, 1999 | |
| | | Polymeropoulos et al., Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. | |
| | | Science, 276: 2045-2047, 1997 | |
| | | Pothos et al., Synaptic vesicle transporter expression regulates vesicle phenotype and quantal size. | |
| | | J. Neurosci., 20: 7297-7306, 2000 | |

Examiner
SignatureDate
Considered

2/2/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

| | | | | | |
|------------------------------|----|----|----|------------------------|-------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| | | | | Application Number | 10/737,262 |
| | | | | Filing Date | 12/15/03 |
| | | | | First Named Inventor | Leonidas Stefanis |
| | | | | Art Unit | 1632-1649 |
| | | | | Examiner Name | to be assigned |
| Sheet | 10 | of | 17 | Attorney Docket Number | 5199-26 |

| NON PATENT LITERATURE DOCUMENTS | | | | | |
|---------------------------------|-----------------------|---|--|--|--|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | |
| PK | | Rathke-Hartlieb et al., Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant-synuclein transgenic mice. | | | |
| | | J. Neurochem., 77: 1181-1184, 2001 | | | |
| | | Rideout et al., Proteasomal inhibition leads to formation of ubiquitin / alpha-synuclein-immunoreactive inclusions in PC12 cells. | | | |
| | | J. Neurochem., 78: 899-908, 2001 | | | |
| | | Rukenstein et al., Multiple agents rescue PC12 cells from serum-free cell death by translation- and transcription-independent mechanisms. | | | |
| | | J. Neurosci., 11: 2552-2563, 1991 | | | |
| | | Saha et al., Induction of neuronal death by alpha-synuclein. | | | |
| | | Eur. J. Neurosci., 12: 3073-3077, 2000 | | | |
| | | Seglen et al., Structural aspects of autophagy. | | | |
| ✓ | | Adv. Exp. Med. Biol., 389: 103-111, 1996 | | | |

| | | | |
|--------------------|---|-----------------|--------|
| Examiner Signature |  | Date Considered | 2/2/06 |
|--------------------|---|-----------------|--------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|----|----|----|--------------------------|-------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | Application Number | 10/737,262 |
| (Use as many sheets as necessary) | | | | Filing Date | 12/15/03 |
| | | | | First Named Inventor | Leonidas Stefanis |
| | | | | Art Unit | 1632-1649 |
| | | | | Examiner Name | to be assigned |
| Sheet | 11 | of | 17 | Attorney Docket Number | 5199-26 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| DK | | Shimura et al., Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for parkinson's disease. | |
| | | Science, 293: 263-269, 2001 | |
| | | Shimura et al., Familial Parkinson disease gene product, parkin, is an ubiquitin-protein ligase. | |
| | | Nat. Genet., 25: 302-305, 2000 | |
| | | Spillantini et al., Alpha-Synuclein in Lewy bodies. | |
| | | Nature, 388: 839-840, 1997 | |
| | | Stefanis et al., Synuclein 1 is selectively upregulated in response to NGF treatment in PC12 cells. | |
| ✓ | | J. Neurochem., 76: 1165-1176, 2001 | |
| | | | |
| | | | |

| | | | |
|--------------------|---|-----------------|--------|
| Examiner Signature |  | Date Considered | 2/2/06 |
|--------------------|---|-----------------|--------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|----|----|----|--------------------------|-------------------|
| Substitute for form 1449/PTO | | | | <i>Complete If Known</i> | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | Application Number | 10/737,262 |
| (Use as many sheets as necessary) | | | | Filing Date | 12/15/03 |
| | | | | First Named Inventor | Leonidas Stefanis |
| | | | | Art Unit | 1632-1649 |
| | | | | Examiner Name | to be assigned |
| Sheet | 12 | of | 17 | Attorney Docket Number | 5199-26 |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-----------------------|---|--|--|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | |
| DK | | Stefanis et al., Caspase-2 (Nedd2) processing and death of trophic factor-deprived PC12 cells and sympathetic neurons occur independently of caspase-3 (CPP-32)-like activity. | | |
| | | J. Neurosci., 18: 9204-9215, 1998 | | |
| | | Sulzer and Pothos, Presynaptic mechanisms that regulate quantal size. | | |
| | | Rev. Neurosci., 11: 159-212, 2000 | | |
| | | Tabrizi et al., Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. | | |
| | | Hum. Mol. Genet., 9: 2683-2689, 2000 | | |
| | | Tanaka et al., Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. | | |
| | | Hum. Mol. Genet., 10: 919-926, 2001 | | |

| | | | |
|--------------------|---|-----------------|--------|
| Examiner Signature |  | Date Considered | 2/2/06 |
|--------------------|---|-----------------|--------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|------------------------------|----|----|----|------------------------|----------------------|
| Substitute for form 1449/PTO | | | | Complete If Known | |
| | | | | Application Number | 10/737,262 |
| | | | | Filing Date | 12/15/03 |
| | | | | First Named Inventor | Leonidas Stefanis |
| | | | | Art Unit | 1092 1649 |
| | | | | Examiner Name | to be assigned |
| Sheet | 13 | of | 17 | Attorney Docket Number | 5199-26 |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-----------------------|---|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | T ² |
| DK | | Tennyson et al., Structural abnormalities associated with congenital megacolon in transgenic mice that overexpress the Hoxa-4 gene. | | |
| | | Dev. Dyn., 98: 128-153, 1993 | | |
| | | Tischler, et al., Morphological and cytochemical properties of a clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth | | |
| | | factor. | | |
| | | Lab. Invest., 39(2): 77-89, 1978 | | |
| | | Trojanowski et al., Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. | | |
| | | Cell Death Differ., 5: 832-837, 1998 | | |
| | | Wojcik et al., Ubiquitin-mediated proteolysis centers in HeLa cells: indication from studies of an inhibitor of the chymotrypsin-like activity of | | |
| | | the proteasome. | | |
| ✓ | | Eur. J. Cell. Biol., 71: 311-318, 1996 | | |

| | | | |
|--------------------|---|-----------------|--------|
| Examiner Signature |  | Date Considered | 2/2/08 |
|--------------------|---|-----------------|--------|


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

| | | | | | |
|--|----|----|----|--------------------------|-------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/737,262 |
| | | | | Filing Date | 12/15/03 |
| | | | | First Named Inventor | Leonidas Stefanis |
| | | | | Art Unit | 1632-1649 |
| | | | | Examiner Name | to be assigned |
| Sheet | 14 | of | 17 | Attorney Docket Number | 5199-26 |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|--|-----------------------|---|--|--|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | |
| DK | | Xue et al., Autophagy is activated by apoptotic signaling in sympathetic neurons: an alternative mechanism of death execution. | | |
| | | Mol. Cell. Neurosci., 14: 180-198, 1999 | | |
| | | Zhou et al., Over expression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. | | |
| | | Brain Res., 866: 33-43, 2000 | | |
| | | Batistatou and Greene, Aurintricarboxylic acid rescues PC12 cells and sympathetic neurons from cell death caused by nerve growth factor deprivation: correlation with suppression of endonuclease activity. | | |
| | | J. Cell. Biol., 115: 461-471, 1991 | | |
| | | Bennett et al., Degradation of alpha-synuclein by proteasome. | | |
| ✓ | | J. Biol. Chem., 274: 33855-33858, 1999 | | |

| | | | |
|--------------------|---|-----------------|--------|
| Examiner Signature |  | Date Considered | 2/2/06 |
|--------------------|---|-----------------|--------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|------------------------------|----|----|----|------------------------|-------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| | | | | Application Number | 10/737,262 |
| | | | | Filing Date | 12/15/03 |
| | | | | First Named Inventor | Leonidas Stefanis |
| | | | | Art Unit | 1892-1649 |
| | | | | Examiner Name | to be assigned |
| Sheet | 15 | of | 17 | Attorney Docket Number | 5199-26 |

| NON PATENT LITERATURE DOCUMENTS | | | | | |
|---------------------------------|-----------------------|---|--|--|--|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | |
| DK | | Drexler, Activation of the cell death program by inhibition of proteasome function. | | | |
| | | Proc. Natl. Acad. Sci., USA, 94: 855-860, 1997 | | | |
| | | Giasson et al., Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. | | | |
| | | J. Biol. Chem., 274: 7619-7622, 1999 | | | |
| | | Greene, Nerve growth factor prevents the death and stimulates the neuronal differentiation of clonal PC12 pheochromocytoma cells in serum-free medium. | | | |
| | | J. Cell Biol., 78: 747-755, 1978 | | | |
| | | Imai et al., Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. | | | |
| ✓ | | J. Biol. Chem., 276: 35661-35664, 2000 | | | |
| | | | | | |
| | | | | | |

| | | | |
|--------------------|---|-----------------|--------|
| Examiner Signature |  | Date Considered | 2/2/06 |
|--------------------|---|-----------------|--------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | | |
|---|----|----|----|--|--------------------------|-------------------|
| <p>Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.</p> <p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(Use as many sheets as necessary)</p> | | | | | Complete if Known | |
| | | | | | Application Number | 10/737,262 |
| | | | | | Filing Date | 12/15/03 |
| | | | | | First Named Inventor | Leonidas Stefanis |
| | | | | | Art Unit | 1632-1649 |
| | | | | | Examiner Name | to be assigned |
| Sheet | 16 | of | 17 | | Attorney Docket Number | 5199-26 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| JK | | Lopes et al., p53-dependent induction of apoptosis by proteasome inhibitors. | |
| | | J. Biol. Chem., 272: 12893-12896, 1997 | |
| | | Mesner et al., Nerve growth factor withdrawal-induced cell death in neuronal PC12 cells resembles that in sympathetic neurons. | |
| | | J. Cell. Biol., 119: 1669-1680, 1992 | |
| | | Obin et al., Neurite outgrowth in PC12 cells: distinguishing the roles of ubiquitylation and ubiquitin-dependent proteolysis. | |
| | | J. Biol. Chem., 274: 11789-11795, 1999 | |
| | | Spillantini et al., Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. | |
| ✓ | | Proc. Natl. Acad. Sci. USA, 95: 6469-6473, 1998 | |
| | | | |
| | | | |

| | | | |
|--------------------|---|-----------------|--------|
| Examiner Signature |  | Date Considered | 2/2/06 |
|--------------------|---|-----------------|--------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|----|----|----|--------------------------|-------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/737,262 |
| | | | | Filing Date | 12/15/03 |
| | | | | First Named Inventor | Leonidas Stefanis |
| | | | | Art Unit | 1632 1649 |
| | | | | Examiner Name | to be assigned |
| Sheet | 17 | of | 17 | Attorney Docket Number | 5199-26 |

| NON PATENT LITERATURE DOCUMENTS | | | | | | |
|--|-----------------------|---|--|--|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | | T ² |
| DK | | Stefanis et al., Induction of CPP32-like activity in PC12 cells by withdrawal of trophic support. | | | | |
| | | J. Biol. Chem., 271: 30663-30671, 1996 | | | | |
| | | Ueda, et al., Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer's Disease. | | | | |
| | | Proc. Natl. Acad. Sci. USA, 90: 11282-11286, 1993 | | | | |
| | | Zhang et al., parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, | | | | |
| | | CDCrel-1. | | | | |
| ✓ | | Proc. Natl. Acad. Sci. USA, 97: 13354-13359, 2000 | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| | | | |
|--------------------|---|-----------------|--------|
| Examiner Signature |  | Date Considered | 2/2/06 |
|--------------------|---|-----------------|--------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.